Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
New York, Palo Alto, and San Diego – Paul Hastings LLP, a leading global law firm, announced today that the firm advised Merck Animal Health, a division of Merck & Co., Inc., on its acquisition of the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews from Virbac for $400 million.
The transaction further solidifies Merck Animal Health’s position in the U.S. Companion Animal Health category, pairing the SENTINEL branded products with Merck Animal Health’s BRAVECTO® product line for comprehensive, continuous parasite protection.
The closing of the transaction is subject to antitrust clearance and other customary closing conditions and is expected to close by mid-year 2020.
The Paul Hastings team was led by Corporate partner
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.